University of Michigan-Rogel Cancer Center Trials

University of Michigan-Rogel Cancer Center	Welcome, Profile Billing Logout

University of Michigan-Rogel Cancer Center

Welcome, Profile Billing Logout

0 Trials

1 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Matza-Wambaja, Ashley

NKT2152-202, NCT05935748: Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Active, not recruiting

172

NKT2152, palbociclib, IBRANCE®, sasanlimab

NiKang Therapeutics, Inc., Pfizer

CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Neoplasms, Carcinoma, Renal Cell, Neoplasms, Glandular and Epithelial, Neoplasm by Histology, Adenocarcinoma, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Urologic Diseases

06/25

06/26

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites